Diabetes Dialogue: SURMOUNT-2 Reaction, Omnipod GO, and Verapamil for T1D

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.

Episode metadata supplied by the publisher feed · Published May 3, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Diabetes Dialogue: SURMOUNT-2 Reaction, Omnipod GO, and Verapamil for T1D

0:00 31:13

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 31 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on May 3, 2023.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!